Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Activation in transformed cells of normal stem cells' self-renewal pathways might contribute to the survival life cycle of cancer stem cells and promote tumor progression. The BMI-1 oncogene-driven gene expression pathway is essential for the self-renewal of hematopoietic and neural stem cells. We applied a mouse/human comparative translational genomics approach to identify an 11-gene signature that consistently displays a stem cell-resembling expression profile in distant metastatic lesions as revealed by the analysis of metastases and primary tumors from a transgenic mouse model of prostate cancer and cancer patients. To further validate these results, we examined the prognostic power of the 11-gene signature in several independent therapy-outcome sets of clinical samples obtained from 1,153 cancer patients diagnosed with 11 different types of cancer, including 5 epithelial malignancies (prostate, breast, lung, ovarian, and bladder cancers) and 5 nonepithelial malignancies (lymphoma, mesothelioma, medulloblastoma, glioma, and acute myeloid leukemia). Kaplan-Meier analysis demonstrated that a stem cell-like expression profile of the 11-gene signature in primary tumors is a consistent powerful predictor of a short interval to disease recurrence, distant metastasis, and death after therapy in cancer patients diagnosed with 11 distinct types of cancer. These data suggest the presence of a conserved BMI-1-driven pathway, which is similarly engaged in both normal stem cells and a highly malignant subset of human cancers diagnosed in a wide range of organs and uniformly exhibiting a marked propensity toward metastatic dissemination as well as a high probability of unfavorable therapy outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated expression of this signature is associated with cancer development and chemotherapy resistance in different types of cancer, including hematological malignancies.11”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 4×
“We therefore sought to investigate whether measurements of expression of the 11-gene MTTS/PNS signature would be informative in the prediction of the patients’ prognosis in a group of 97 young women diagnosed with sporadic lymph node– negative early-stage breast cancer who were analyzed in a recent expression profilin…”
BackgroundMethodInfluentialA Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Systematic determination of genetic network architecture
Tavazoie, S., Hughes, J. D., Campbell, M. J., Cho, R. J., & Church, G. M. (1999) · Nature Genetics · doi:10.1038/10343 · Cited by 2,507 · cited 1×
“We calculated the significance of the overlap between the lists of stem cell–associated and prostate cancer–associated genes by using the hypergeometric distribution test (54).”
MethodA molecular signature of metastasis in primary solid tumors
Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003) · Nature Genetics · doi:10.1038/ng1060 · Cited by 2,449
Shipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C. T., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., et al. (2002) · Nature Medicine · doi:10.1038/nm0102-68 · Cited by 2,428
Cited by
Items 301–400 of 914
Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target
Asim, M., Massie, C. E., Orafidiya, F. A., Pértega‐Gomes, N., Warren, A. Y., Esmaeili, M., Selth, L. A., Zecchini, H. I., Luko, K., Qureshi, A., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv371 · Cited by 60
Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma
Kahn, S. A., Wang, X., Nitta, R. T., Gholamin, S., Theruvath, J. L., Hütter, G., Azad, T. D., Wadi, L., Bolin, S., Ramaswamy, V., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06564-9 · Cited by 65
Dynamic modules of the coactivator SAGA in eukaryotic transcription
Cheon, Y., Kim, H., Park, K., Kim, M., & Lee, D. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0463-4 · Cited by 66
Prostatic preneoplasia and beyond
Joshua, A. M., Evans, A., van der Kwast, T., Zieleńska, M., Meeker, A. K., Chinnaiyan, A. M., & Squire, J. A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.12.001 · Cited by 82
“These pathways are all likely to be co-regulated to maintain stem cell homeostasis and their dysregulation may be crucial to the emergence of a CIC phenotype or morphological characteristics of more advanced disease [77–79].”
BackgroundExpression profiling technology: its contribution to our understanding of breast cancer
Rakha, E. A., El‐Sayed, M. E., Reis-Filho, J. S., & Ellis, I. O. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02894.x · Cited by 70
Qi, X., Li, J., Zhou, C., Lv, C., & Tian, M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.08.021 · Cited by 55
“BMI-1 is a member of the Polycomb Group (PcG) family, which is overexpressed in various types of human cancer [23,24].”
BackgroundChapman, E., Kelly, G. P., & Knowles, M. A. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2168 · Cited by 60
“BMI1 is also associated with a stem-like expression profile that predicts poor outcome and treatment failure in multiple tumor types including bladder cancer (49).”
BackgroundEvaluation of protein biomarkers of prostate cancer aggressiveness
Rizzardi, A. E., Rosener, N. K., Koopmeiners, J. S., Isaksson Vogel, R., Metzger, G. J., Forster, C. L., Marston, L. O., Tiffany, J. R., McCarthy, J. B., Turley, E. A., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-244 · Cited by 55
“Other groups have developed multi-biomarker signatures of PCa aggressiveness using gene expression profiling as a method for biomarker discovery; these studies have surprisingly little overlap be-tween gene sets [6,9,10,13,15-18].”
Diagnostic applications of microarrays
Petrík, J. (2006) · Transfusion Medicine · doi:10.1111/j.1365-3148.2006.00673.x · Cited by 62
“Recently, Glinsky et al. (2005) succeeded in identifying a 11-gene panel that consistently displays a stem-celltype expression profile in metastatic lesions, suggesting the existence of tumour stem cells responsible for tumour progression and metastasis.”
BackgroundPerspectives on the mesenchymal origin of metastatic cancer
Huysentruyt, L. C., & Seyfried, T. N. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9254-z · Cited by 59
“Fusions among macrophages and tumor cells could also account for histological structures in metastatic sites that resemble the histology of the primary tumor tissue as it has been shown, through reprogramming strategies, that macrophages are capable of producing fully functional epithelial cells at secondary sites whi…”
BackgroundLiu, S., Tetzlaff, M. T., Wang, T., Yang, R., Xie, L., Zhang, G., Krepler, C., Xiao, M., Beqiri, M., Xu, W., et al. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12379 · Cited by 54
Helzer, K. T., Barnes, H. E., Day, L., Harvey, J. P., Billings, P. R., & Forsyth, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0801 · Cited by 57
Hec1/Ndc80 is overexpressed in human gastric cancer and regulates cell growth
Qu, Y., Li, J., Cai, Q., & Liu, B. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0809-y · Cited by 54
“Moreover, Hec1 overexpression was associated with poor clinical prognosis in non-small cell lung cancers, breast cancers and patients with multiple cancers [43, 44].”
BackgroundHistone Monoubiquitination in Chromatin Remodelling: Focus on the Histone H2B Interactome and Cancer
Marsh, D. J., Ma, Y., & Dickson, K.-A. (2020) · Cancers · doi:10.3390/cancers12113462 · Cited by 62
“It has been implicated as part of the “death-from-cancer” signature, a stem cell gene expression signature consisting of 11 genes prognostic of rapid relapse and resistance to therapy in different solid tumours [92,166].”
BackgroundOliva, C. R., Markert, T., Gillespie, G. Y., & Griguer, C. E. (2015) · Oncotarget · doi:10.18632/oncotarget.3015 · Cited by 56
“Since one major function of supercomplex formation appears to be the limitation of ROS production [39, 40], we further speculate that supercomplex formation may increase ETC coupling, decrease mitochondrial proton leak, and decrease the generation of mitochondrial ROS in CcO carrying the COX4-1 isoform.”
BackgroundStem Cell Origin of Death-from-Cancer Phenotypes of Human Prostate and Breast Cancers
Glinsky, G. V. (2007) · Stem Cell Reviews and Reports · doi:10.1007/s12015-007-0011-9 · Cited by 64
“HCFC1, one of the up-regulated genes of the 11-gene death-from-cancer signature [5], was shown to activate Cyclin D1 by blocking the Miz-1-mediated transactivation of the cell cycle inhibitor p15 and relieving Cyclin D1 from inhibitory action of the p15 protein [60].”
BackgroundMethodInfluentialSelf-citationBmi1 marks intermediate precursors during differentiation of human brain tumor initiating cells
Venugopal, C., Li, N., Wang, X., Manoranjan, B., Hawkins, C. E., Gunnarsson, Þ., Hollenberg, R. D., Klurfan, P., Murty, N., Kwiecień, J. M., et al. (2011) · Stem Cell Research · doi:10.1016/j.scr.2011.09.008 · Cited by 57
“, 2006), and the identification of a Bmi1-driven gene signature through a mouse/human comparative translational genomics approach which has been validated in numerous human cancers (Glinsky et al., 2005).”
BackgroundTargeting self-renewal, an Achilles' heel of cancer stem cells
Wicha, M. S. (2014) · Nature Medicine · doi:10.1038/nm.3434 · Cited by 56
PTEN inhibits BMI1 function independently of its phosphatase activity
Fan, C., He, L., Kapoor, A., Rybak, A. P., Melo, J. D., Cutz, J., & Tang, D. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-98 · Cited by 57
“Increases in BMI1 mRNA were detected in prostate cancer cell lines, xenografts and human primary prostate carcinomas, as well as primary prostate tumors derived from the TRAMP transgenic mouse model [18].”
BackgroundResultInfluentialBiomarkers for Malignant Pleural Mesothelioma: Current Status
Greillier, L., Baas, P., Welch, J. J., Hasan, B., & Passioukov, A. (2008) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256303 · Cited by 59
Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation
Srinivasan, M., Bharali, D. J., Sudha, T., Khedr, M., Guest, I., Sell, S., Glinsky, G. V., & Mousa, S. A. (2017) · Oncotarget · doi:10.18632/oncotarget.16317 · Cited by 52
“One such molecule, Bmi1, is a Polycomb group (PcG) transcriptional repressor protein that silences gene expression by inducing chromatin modifications, hindering transcription factors and RNA polymerase binding [12].”
Self-citationStem cell sources and therapeutic approaches for central nervous system and neural retinal disorders
Yu, D. X., & Silva, G. A. (2008) · Neurosurgical FOCUS · doi:10.3171/foc/2008/24/3-4/e10 · Cited by 59
Identification of Breast Cancer Peptide Epitopes Presented by HLA-A*0201
Hawkins, O. E., VanGundy, R. S., Eckerd, A., Bardet, W., Buchli, R., Weidanz, J. A., & Hildebrand, W. H. (2008) · Journal of Proteome Research · doi:10.1021/pr700761w · Cited by 56
Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint
Lim, K., Song, M.-H., & Baek, K. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2129-2 · Cited by 56
Copy number alterations of the polycomb gene BMI1 in gliomas
Häyry, V., Tanner, M., Blom, T., Tynninen, O., Roselli, A., Ollikainen, M., Sariola, H., Wartiovaara, K., & Nupponen, N. N. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0376-0 · Cited by 41
microRNA-141 regulates BMI1 expression and induces senescence in human diploid fibroblasts
Dimri, M., Carroll, J. D., Cho, J., & Dimri, G. P. (2013) · Cell Cycle · doi:10.4161/cc.26592 · Cited by 56
Characterization of mammary cancer stem cells in the MMTV-PyMT mouse model
Ma, J., Lanza, D. G., Guest, I., Uk-Lim, C., Glinskii, A. B., Glinsky, G. V., & Sell, S. (2012) · Tumor Biology · doi:10.1007/s13277-012-0458-4 · Cited by 50
“Previous studies have documented the importance of Bmi-1 in cancers, correlating higher expression of Bmi-1 to poor clinical outcome of patients with breast, prostate, lung, ovarian, or bladder cancers [61].”
BackgroundSelf-citationPrognostic significance of miR-194 in endometrial cancer
Zhai, H., Karaayvaz, M., Dong, P., Sakuragi, N., & Ju, J. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-12 · Cited by 53
“Overexpression of BMI-1 has been found in many human cancers, including lung cancer, prostate cancer, breast cancer, ovarian cancer and EC [28-32].”
Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer
Kristiansen, G. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.168 · Cited by 53
Kosinsky, R. L., Helms, M., Zerche, M., Wohn, L., Dyas, A., Prokakis, E., Kazerouni, Z. B., Bedi, U., Wegwitz, F., & Johnsen, S. A. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2141-9 · Cited by 51
Liang, J., Ning, Z., Gao, W., Ling, J., Wang, A., Luo, H., Liang, Y., Yan, Q., & Wang, Z. (2014) · Oncology Reports · doi:10.3892/or.2014.3508 · Cited by 51
Malignant Pleural Mesothelioma: From the Bench to the Bedside
Astoul, P. J., Roca, E., Galateau-Sallé, F., & Scherpereel, A. (2012) · Respiration · doi:10.1159/000339259 · Cited by 57
βTrCP regulates BMI1 protein turnover via ubiquitination and degradation
Sahasrabuddhe, A. A., Dimri, M., Bommi, P. V., & Dimri, G. P. (2011) · Cell Cycle · doi:10.4161/cc.10.8.15372 · Cited by 52
“It has been proposed that BMI1 overexpression promotes stem-ness in tumor cells, which promotes therapy resistance in cancer patients.(2) Recent mouse xenograft studies using BMI1 and H-RAS co-overexpressing human mammary epithelial cells (HMECs) strongly support the oncogenic roles of BMI1 in breast cancer developmen…”
BackgroundMedulloblastoma stem cells: Modeling tumor heterogeneity
Manoranjan, B., Venugopal, C., McFarlane, N., Doble, B. W., Dunn, S. E., Scheinemann, K., & Singh, S. K. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.07.010 · Cited by 53
Choi, Y. J., Choi, Y., Cho, E. Y., Shin, Y. K., Sung, K. W., Hwang, Y. K., Lee, S. J., Kong, G., Lee, J. E., Kim, J. S., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9909-4 · Cited by 49
“circulating Bmi-1 mRNA and expression of Bmi-1 gene signature in tissues were studied as poor prognostic factors [22, 23].”
BackgroundHu, J., Yang, D., Zhang, H., Liu, W., Zhao, Y., Lu, H., Meng, Q., Pang, H., Chen, X., Liu, Y., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.02.019 · Cited by 54
Christensen, K. G., Aaberg-Jessen, C., Andersen, C. L., Goplen, D., Bjerkvig, R., & Kristensen, B. W. (2010) · Neurosurgery · doi:10.1227/01.neu.0000368393.45935.46 · Cited by 51
Kreppel, M., Drebber, U., Wedemeyer, I., Eich, H., Backhaus, T., Zöller, J. E., & Scheer, M. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.06.508 · Cited by 50
Rebetz, J., Tian, D., Persson, A., Widegren, B., Salford, L. G., Englund, E. M., Nord, D. G., & Fan, X. (2008) · Cited by 50
Ramaiah, M. J., & Sakthiprasad, V. (2018) · Gene · doi:10.1016/j.gene.2018.08.022 · Cited by 51
Wnt activation as a therapeutic strategy in medulloblastoma
Manoranjan, B., Venugopal, C., Bakhshinyan, D., Adile, A., Richards, L. M., Kameda-Smith, M. M., Whitley, O., Dvorkin‐Gheva, A., Subapanditha, M., Savage, N. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17953-4 · Cited by 57
Ning, Z., Wang, A., Liang, J., Xie, Y., LIU, J.-W., Feng, L., Yan, Q., & WANG, Z. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2531 · Cited by 57
Cariati, M., & Purushotham, A. D. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02895.x · Cited by 67
“Translational studies have shown how a higher fraction of CD24) ⁄ CD44+ cells is associated with shorter disease-free interval and overall survival and with greater incidence of distant metastasis.(62,63) Furthermore, a recent study looking into the overall gene signature of CD44+ and CD24+ cells (normal 104 M Cariati…”
Tomida, S., Yanagisawa, K., Koshikawa, K., Yatabe, Y., Mitsudomi, T., Osada, H., & Takahashi, T. (2007) · Oncogene · doi:10.1038/sj.onc.1210242 · Cited by 50
“…our metastasis signature gene set contains related to the ubiquitin-proteasome pathway, including Oncogene UBE1 and PSMD2, whereas others like USP22 and RNF2 were included in the 11-gene signature identified by Glinsky et al. (2005) through analysis of highly metastatic prostate cancer cell line.”
BackgroundTargeted therapy of cancer: new roles for pathologists—prostate cancer
Rubin, M. A. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.11 · Cited by 57
Histone modifications: Targeting head and neck cancer stem cells
Le, J. M., Squarize, C. H., & Castilho, R. M. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i5.511 · Cited by 53
Expression of BMI-1 in normal skin and inflammatory and neoplastic skin lesions
Reinisch, C. M., Uthman, A., Erović, B. M., & Pammer, J. (2006) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2006.00587.x · Cited by 49
“A stem cell-like expression profile including high BMI-1 expression has been reported to be associated with an adverse prognosis in multiple types of cancer.(12) The most common human cancers are epithelial skin tumors.”
BackgroundA short guide to hereditary diffuse gastric cancer
Guilford, P., Blair, V., More, H., & Humar, B. (2007) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-5-4-183 · Cited by 49
Glinsky, G. V., & Barakat, T. S. (2019) · Stem Cell Research · doi:10.1016/j.scr.2019.101456 · Cited by 45
“, 2017) are significantly enriched near DNA sequences operating as active hESC enhancers (data not shown), consistent with a role of stem cell regulatory networks in development of clinically lethal cancer phenotypes (Glinsky, 2015b, 2016a,c; Glinsky et al., 2005).”
BackgroundSelf-citationThe emerging role of tumor-suppressive microRNA-218 in targeting glioblastoma stemness
Gao, X., & Jin, W. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.011 · Cited by 51
“Bmi1 is a polycomb group epigenetic gene silencer that is highly expressed in various types of human cancers [84] and required for”
BackgroundHascher, A., Haase, A.-K., Hebestreit, K., Rohde, C., Klein, H., Rius, M., Jungen, D., Witten, A., Stoll, M., Schulze, I., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1483 · Cited by 53
“Gene expression profiles of metastatic cancer cells are similar to gene expression profiles of cancer stem cells (9, 10).”
BackgroundGene expression in “young adult type” breast cancer: a retrospective analysis
Johnson, R. H., Hu, P., Fan, C., & Anders, C. K. (2015) · Oncotarget · doi:10.18632/oncotarget.4051 · Cited by 53
“[28][29][30][31]”
Ning, J., Zhang, J., Liu, W., Lang, Y., Xue, Y., & Xu, S. (2012) · European Journal of Histochemistry · doi:10.4081/ejh.2012.e46 · Cited by 48
A Polycomb-mir200 loop regulates clinical outcome in bladder cancer
Martínez‐Fernández, M., Dueñas, M., Feber, A., Segovia, C., García‐Escudero, R., Rubio, C., López-Calderón, F., Díaz-García, C. V., Villacampa, F., Duarte, J. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5546 · Cited by 47
“BMI1 is a reported miR-200 target gene [32], and increased BMI1 expression has been associated with poor prognosis in bladder cancer patients [20, 33].”
BackgroundMeng, Q., Wang, H., Song, Z., Shan, Z., Yuan, Z., Zheng, Q., & Huang, X. (2015) · Europe PMC (PubMed Central) · Cited by 47
Koutelou, E., Wang, L., Schibler, A. C., Chao, H., Kuang, X., Lin, K., Lu, Y., Shen, J., Jeter, C. R., Salinger, A. P., et al. (2019) · Development · doi:10.1242/dev.174037 · Cited by 52
“Usp22 was first described as a member of an 11-gene ‘death from cancer’ signature that was defined by gene expression microarrays (Glinsky et al., 2005).”
BackgroundA Novel Gene Signature for Molecular Diagnosis of Human Prostate Cancer by RT-qPCR
Rizzi, F., Belloni, L., Crafa, P., Lazzaretti, M., Remondini, D., Ferretti, S., Cortellini, P., Corti, A., & Bettuzzi, S. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003617 · Cited by 47
“Previous studies by DNA microarray have identified molecular signatures that significantly correlated with CaP progression [27] or grading [28], leading to identification of informative genes (sometimes with unknown functions) that are still awaiting further studies for elucidating their role in CaP progression [29].”
BackgroundMolecular predictors of response and outcome in ovarian cancer
Canevari, S., Gariboldi, M., Reid, J. F., Bongarzone, I., & Pierotti, M. A. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.03.003 · Cited by 49
“Some more recent studies are attempting to elaborate ultiple gene classifiers able to predict either relapse after hemotherapy or survival [135,140,142–144].”
BackgroundRezaeian, I., Mucaki, E. J., Baranova, K., Pham, H. Q., Angelov, D., Ngom, A., Rueda, L. G., & Rogan, P. K. (2016) · F1000Research · doi:10.12688/f1000research.9417.3 · Cited by 53
NUSAP1 expression is upregulated by loss of RB1 in prostate cancer cells
Gordon, C. A., Gulzar, Z. G., & Brooks, J. D. (2015) · The Prostate · doi:10.1002/pros.22938 · Cited by 53
“In a recent study, we found that nucleolar and spindle-associated protein 1 (NUSAP1), an important regulator of mitosis [4], is among 28 transcripts overexpressed in recurrent prostate cancer tumors [3], and validated its prognostic potential in two independent prostate cancer datasets [5,6].”
BackgroundPhosphorylation of Nanog is essential to regulate Bmi1 and promote tumorigenesis
Xie, X., Piao, L., Cavey, G. S., Old, M. O., Teknos, T. N., Mapp, A. K., & Pan, Q. (2013) · Oncogene · doi:10.1038/onc.2013.173 · Cited by 48
“A Bmi1-driven stem cellassociated gene expression signature is highly predictive of disease recurrence, distant metastasis, and overall survival in numerous epithelial and non-epithelial malignancies (33).”
BackgroundPrognostic significance of USP22 as an oncogene in papillary thyroid carcinoma
Wang, H., Li, Y.-P., Chen, J., Yuan, S., Ling, W., Zhang, J.-L., Yao, Q., Li, N., Bian, J., Fan, J., et al. (2013) · Tumor Biology · doi:10.1007/s13277-013-0696-0 · Cited by 47
“It has been demonstrated that the USP22 deubiquitinating enzyme can remove ubiquitin efficiently both from the core histone H2A and H2B in vitro and regulate transcription via alterations in the levels of histone ubiquitylation [5, 6].”
Li-jun, L. I. N. G., Wang, S., Liu, X., En-chao, S. H. E. N., Ding, Q., Lü, C., Xu, J. Y., Qin-hong, C. A. O., Hai-qing, Z. H. U., & Wang, F. (2008) · Chinese Medical Journal · doi:10.1097/00029330-200810020-00006 · Cited by 46
USP22 positively modulates ERα action via its deubiquitinase activity in breast cancer
Wang, S., Zhong, X., Wang, C., Luo, H., Lin, L., Sun, H., Sun, G., Zeng, K., Zou, R., Liu, W., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0568-2 · Cited by 47
“USP22 has been reported as a member of 11 “Deathfrom-Cancer” genes [19, 20].”
Backgroundvan Galen, J. C., Muris, J. J. F., Oudejans, J. J., Vos, W., Giroth, C., Ossenkoppele, G. J., Otte, A. P., Raaphorst, F. M., & Meijer, C. J. L. M. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.038752 · Cited by 50
BMI1 induces an invasive signature in melanoma that promotes metastasis and chemoresistance
Ferretti, R., Bhutkar, A. J., McNamara, M. C., & Lees, J. A. (2015) · Genes & Development · doi:10.1101/gad.267757.115 · Cited by 52
“In support of this latter role, BMI1 ’ s expression increases with progression in many human tumors, and this is an excellent predictor of both progression and poor prognosis (Glinsky et al. 2005).”
Gene expression profiling to dissect the complexity of cancer biology: Pitfalls and promise
Raspé, E., Decraene, C., & Berx, G. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.011 · Cited by 51
Comparative Proteomics Analysis of Gastric Cancer Stem Cells
Morisaki, T., Yashiro, M., Kakehashi, A., Inagaki, A., Kinoshita, H., Fukuoka, T., Kasashima, H., Masuda, G., Sakurai, K., Kubo, N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110736 · Cited by 52
“role in the malignant potential of cancer cells, including distant metastasis and chemoresistance [4].”
BackgroundTuck (2009) · International Journal of Oncology · doi:10.3892/ijo_00000340 · Cited by 45
“Comparisons with a data set we constructed, comprised of gene lists from the literature on expression profiles/signatures of breast cancer cells with stem cell-like properties (23,27,28), revealed 61 genes differentially expressed between 468LN and 468GFP cells that were represented on the data set of cancer stem cell…”
MethodResultHartel, M., Narla, G., Wente, M. N., Giese, N. A., Martignoni, M. E., Martignetti, J. A., Friess, H., & Friedman, S. L. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.030 · Cited by 48
Lauss, M., Ringnér, M., & Höglund, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0606 · Cited by 47
Convergence of BMI1 and CHD7 on ERK Signaling in Medulloblastoma
Badodi, S., Dubuc, A. M., Zhang, X., Rosser, G., Jaeger, M. D. C., Kameda-Smith, M. M., Morrissy, A. S., Guilhamon, P., Suetterlin, P., Li, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.021 · Cited by 49
“Numerous studies have demonstrated that BMI1, which is upregulated in a variety of cancers, has a positive correlation with clinical grade/stage and poor prognosis (Glinsky et al., 2005).”
BackgroundCooper, C. S., Campbell, C., & Jhavar, S. G. (2007) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0946 · Cited by 47
“Signature of “stem cell-ness” In an approach driven by the hypothesis that tumors with stem cell-like characteristics have poor prognoses as compared to those without, Glinsky et al”
BackgroundBelle, J. I., & Nijnik, A. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.03.004 · Cited by 58
Targeting the Spindle Assembly Checkpoint for Breast Cancer Treatment
Marques, S. I., Fonseca, J., Silva, P. M. A., & Bousbaa, H. (2015) · Current Cancer Drug Targets · doi:10.2174/1568009615666150302130010 · Cited by 46
“Nuclear Bub1 immunohistochemical status was suggested as an independent prognostic factor for both disease-free and breast cancer-specific survival of breast cancer patients [32,34,35].”
BackgroundInnovative Therapeutic Strategies in the Treatment of Brain Metastases
Caffo, M., Barresi, V., Caruso, G., Cutugno, M., Fata, G. L., Venza, M., Alafaci, C., & Tomasello, F. F. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14012135 · Cited by 45
“short interval to disease recurrence following therapy, increased likelihood of metastatic disease, and poor response to therapy in multiple types of human cancer, including prostate, lung, ovarian, urinary bladder, lymphoma, mesothelioma, glioma, acute myeloid leukemia, and breast cancer [79].”
BackgroundZafar, A., Wu, F., Hardy, K., Li, J., Tu, W. J., McCuaig, R., Harris, J. L., Khanna, K. K., Attema, J. L., Gregory, P. A., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01693-13 · Cited by 51
“sistance and relapse in breast cancer patients (5, 6).”
BackgroundPGE2-Driven Expression of c-Myc and OncomiR-17-92 Contributes to Apoptosis Resistance in NSCLC
Krysan, K., Kusko, R. L., Grogan, T., O’Hearn, J., Reckamp, K. L., Walser, T. C., Garon, E. B., Lenburg, M. E., Sharma, S. P., Spira, A. E., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0377 · Cited by 43
“In keeping with these findings, c-Myc overexpression has been reported to be a constituent of a stem cell–like signature in aggressive poorly differentiated tumors (15).”
BackgroundThe methylation landscape of tumour metastasis
Cock-Rada, A. M., & Weitzman, J. B. (2013) · Biology of the Cell · doi:10.1111/boc.201200029 · Cited by 52
“Epigenetic programs controlled by PRC2 are associated with aggressive cancer phenotypes and contribute to metastasis in patients (Glinsky, 2005; Glinsky et al., 2005; Sparmann and van Lohuizen, 2006).”
BackgroundMa, Y., Fu, H., Wang, Z., Huang, H., Ni, J., Song, J., Xia, Y., Jin, W., & Cui, D. (2017) · Oncotarget · doi:10.18632/oncotarget.16445 · Cited by 45
“Eleven genes were identified as death-from-cancer signatures predicting poor survival of cancer patients in multiple malignancies including USP22 [10] (Figure 4A).”
InfluentialStein, R. G., Ebert, S., Schlahsa, L., Scholz, C. J., Braun, M., Hauck, P., Horn, E., Monoranu, C., Thiemann, V., Wustrow, M. P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0387 · Cited by 47
D’Onofrio, N., Martino, E., Balestrieri, A., Mele, L. L., Cautela, D., Castaldo, D., & Balestrieri, M. L. (2022) · FEBS Letters · doi:10.1002/1873-3468.14310 · Cited by 48
Neural stem cells as novel cancer therapeutic vehicles
Yip, S. S. F., Sabetrasekh, R., Sidman, R. L., & Snyder, E. Y. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.046 · Cited by 47
Glinsky, G. V., Glinskii, A. B., Berezovskaya, O., Smith, B. A., Jiang, P., Li, X., Yang, M., & Hoffman, R. M. (2005) · Cell Cycle · doi:10.4161/cc.5.2.2320 · Cited by 46
Self-citationEngelsen, I. B., Mannelqvist, M., Stefansson, I. M., Carter, S. L., Beroukhim, R., Oyan, A. M., Otte, A. P., Kalland, K., Akslen, L. A., & Salvesen, H. B. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604360 · Cited by 43
Arnes, J. B., Collett, K., & Akslen, L. A. (2008) · Histopathology · doi:10.1111/j.1365-2559.2007.02957.x · Cited by 42
“As stem cell markers have been associated with a more primitive phenotype, tumour cell expression could indicate de-differentiation, and thus possible increased aggressiveness.(65,66) Whereas haematological malignancies are related to a well-characterized hierarchy of putative precursor cells, such a structure is only…”
BackgroundLi, J., Wang, Z., & Yu, L. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1191-5 · Cited by 42
“…enzyme and a putative cancer stem cell marker, and a member comprising the 11 gene Polycomb/cancer stem cell signature that identifies highly aggressive tumors consistently resistant to therapy and have a high risk of recurrence after surgical resection (Glinsky et al. 2005; Zhang et al. 2008a, b).”
BackgroundLehmann, C. H. K., JOBS, G., Thomas, M., BURTSCHER, H. J., & Kubbies, M. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1654 · Cited by 51
“Finally, an 11-gene signature previously reported to be predictive for therapy failure in multiple cancers (33) was not predictive for the tumorigenicity of our cell models.”
BackgroundLiu, Y., Yang, Y.-M., Xu, H., & Dong, X. (2010) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e3181e202f2 · Cited by 43
“Arecent discovery of a 11-gene polycomb/cancer stem cell signature could predict extremely poor prognosis of patients with a wide variety of cancers.(1) Cancer cells manifesting this signature would manifest an aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control.”
BackgroundPolycomb genes, miRNA, and their deregulation in B-cell malignancies
Wang, G. G., Konze, K. D., & Tao, J. (2015) · Blood · doi:10.1182/blood-2014-10-606822 · Cited by 47
Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma
Liu, W.-L., Guo, X.-Z., Zhang, L.-J., Wang, J.-Y., Zhang, G., Guan, S., Chen, Y.-M., Kong, Q., Xu, L.-H., Li, M.-Z., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-467 · Cited by 41
“In addition, it has been found that Bmi-1 is overexpressed in a variety of human cancers, such as mantle cell lymphomas[18], non-small cell lung cancer[19], B-cell non-Hodgkin’s lymphoma[20], breast cancer[21], colorectal cancer[22], prostate cancer[23], nasopharyngeal carcinoma[16] and gastric carcinoma[24].”
Boellmann, F., Zhang, L., M.A., H. J. C. I., Schroth, G. P., Kenyon, E. M., Andersen, M. E., & Thomas, R. S. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq225 · Cited by 44
“The reduced expression of Ank3 has been part of an 11-gene signature of negative cancer treatment outcome (Glinsky et al., 2005).”
BackgroundLee, Y.-S. E., Chuang, S., Huang, L. Y. L., Lai, C., Lin, Y., Yang, J., Liu, C.-W., Yang, S., Lin, H.-S., Chang, C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401990s · Cited by 41
Jiang, S., Song, C., Gu, X., Wang, M., Miao, D., Lv, J., & Liu, Y. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000489156 · Cited by 44
Epigenetic “bivalently marked” process of cancer stem cell‐driven tumorigenesis
Balch, C., Nephew, K. P., Huang, T. H. ‐., & Bapat, S. A. (2007) · BioEssays · doi:10.1002/bies.20619 · Cited by 42
Stem cell-ness: a "magic marker" for cancer
Lahad, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25455 · Cited by 43
“By contrast, Glinsky and colleagues produce a concrete definition of a gene signature (1).”
BackgroundInfluentialNing, Z., Wang, A., Liang, J., Xie, Y., Liu, J., Feng, L., Yan, Q., & Wang, Z. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4871 · Cited by 41
Is there a role for mammary stem cells in inflammatory breast carcinoma?
Laere, S. V., Limame, R., Marck, E. A. V., Vermeulen, P. B., & Dirix, L. Y. (2010) · Cancer · doi:10.1002/cncr.25180 · Cited by 40
Using induced pluripotent stem cells as a tool for modelling carcinogenesis
Curry, E. L., Moad, M., Robson, C. N., & Heer, R. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i2.461 · Cited by 51
Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells
Liao, C., Chen, L., Luethy, A., Kim, Y., Kani, K., MacLeod, A. R., & Gross, M. E. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0138 · Cited by 45
“Other data suggest that acquisition of stem cell marker expression and stem cell phenotypes are critical in primary prostate cancer tumorigenesis and progression to treatment-resistant, metastatic prostate cancer (Glinsky et al .”
Metadata
- Authors
- Glinsky, G. V., Berezovska, O., & Glinskii, A. B.
- Affiliations
- Sidney Kimmel Cancer Center (US)
- Corresponding author
- Glinsky, Gennadi V.
- ORCID
- Glinsky, Gennadi V.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1503-1521
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1136989
- OpenAlex
- W2166666333
- Cited by
- 916
- References
- 68
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 22 · 2023: 30 · 2022: 25 · 2021: 29 · 2020: 25 · 2019: 27 · 2018: 38 · 2017: 35 · 2016: 30 · 2015: 50 · 2014: 57 · 2013: 51 · 2012: 60
- FWCI
- 34.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (5R01CA89827, R01CA089827)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- cancer stem cells, BMI1, stem cell self-renewal, gene expression signatures, metastasis, treatment failure, prognosis, distant metastasis, recurrence, epithelial malignancies, hematologic malignancies, multi-cancer analysis
- MeSH terms
- Animals, Female, Humans, Male, Mice, Transgenic, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Nuclear Proteins, Prognosis, Proto-Oncogene Proteins, Repressor Proteins, Biomarkers, Tumor, Neoplastic Stem Cells, Gene Expression Regulation, Neoplastic, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Polycomb Repressive Complex 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.